Areas of interest (AOI) & competitive research grants
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
Start Date | End date | ||
Cardiovascular – CAMZYOS (Mavacamten) | Feb 23, 2024 | Mar 04, 2024 | Apr 11, 2024 |
Immunology – Sotyktu (Deucravacitinib) | Feb 26, 2024 | Mar 25, 2024 | Apr 25, 2024 |
Immunology – Sotyktu (Deucravacitinib) – Dermatology | Aug 26, 2024 | Sept 23, 2024 | Nov 14, 2024 |
Immunology – Sotyktu (Deucravacitinib) - Rheumatology | Aug 26, 2024 | Sept 23, 2024 | Nov 14, 2024 |
Sotyktu (Deucravacitinib) ISR Areas of Interest – RFP#1 2024
- Deucravacitinib efficacy and safety in psoriasis, including patient sub-populations
- Demographics (e.g., ethnicity, race, skin types)
- Different types of psoriasis (e.g., guttate, etc.)
- Disease burden (w/comorbidities)
- Psoriasis disease & treatment history
- Additional measures of response (e.g., patient satisfaction, other Patient-Reported Outcomes)
- Deucravacitinib efficacy and safety in rheumatologic diseases
- Clinical practice informing studies to support evidence-based care in psoriatic arthritis
- Clinical and biomarker proof-of-concept evidence with deucravacitinib in other dermatological immune-mediated diseases with pathophysiological involvement of TYK2-mediated pathways (Type 1 IFN, IL-23/IL-17 axis)
- Non-clinical studies furthering the understanding of the role of TYK2 in immune mediated diseases
Out of Scope
- Pediatric studies
- Alternative dosing regimens
- Alopecia Areata
- Vitiligo
- Hidradenitis Suppurativa
- Combination therapy
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here